Orexigen Therapeutics — JP Morgan Healthcare Conference 2015
22 slides from Orexigen Therapeutics's conference presentation, Jan 12, 2015

Slide 1: JP Morgan Healthcare Conference January 2015
JP Morgan Healthcare Conference January 2015 Exhibit 99.1

Slide 2: Forward Looking Statements
For investor purposes only – not for use in product promotion Forward Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. and its recently approved product, Contrave. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “wil

Slide 3: 2014 was a Transformational Year for Orexigen
For investor purposes only – not for use in product promotion US approval of Contrave ® (naltrexone HCl / bupropion HCl extended-release) US launch Positive CHMP opinion for Mysimba™ (naltrexone HCl / bupropion HCl prolonged- release) Balance sheet strengthened – $100 million in milestones received

Slide 4: Orexigen's First Approved Product
For investor purposes only – not for use in product promotion Orexigen’s First Approved Product Full Prescribing Information, including Medication Guide, for Contrave is available at http://www.contrave.com/ .

Slide 5: Contrave Indication and Important Safety Information
For investor purposes only – not for use in product promotion For investor purposes only – not for use in product promotion INDICATION: Contrave is approved by the FDA for use as an adjunct to a reduced- calorie diet and increased physical activity for chronic weight management in adults with an ini

Slide 6: The Obesity Epidemic is One of the Largest Public Health Challenges
For investor purposes only – not for use in product promotion $2 trillion direct economic burden worldwide – 2.8% of global GDP May reduce life expectancy by up to 8 years 3.4 million deaths annually directly attributable to obesity and overweight The Obesity Epidemic is One of the Largest Public He

Slide 7: Favorable Global Action in the Fight against Obesity
For investor purposes only – not for use in product promotion Favorable Global Action in the Fight against Obesity AMA recognized obesity as a disease Treat and Reduce Obesity Act had strong support and reintroduction planned in new Congress AACE guidelines stress importance of weight loss (includin

Slide 8: The Obesity Pharmaceutical Market is Rapidly Developing
For investor purposes only – not for use in product promotion The Obesity Pharmaceutical Market is Rapidly Developing In Europe, Mysimba™ is 1 st new drug with positive CHMP opinion in nearly a decade will be educating HCPs about obesity treatments SALES REPS DRUGS RECENTLY APPROVED BY FDA Large CV

Slide 9: Weight Loss is a Medical Imperative in Obese Patients with Diabetes and Prediabetes
382 m 316 m With diabetes With prediabetes Xendos Trial Weight Loss at one year 4.0 % Weight Loss at one year relative reduction in progression to diabetes 37 % Costs $281 B $144 B $612 B Deaths 198,000 537,000 4.9 M DPP Study 4.3 % relative reduction in progression to diabetes 39 % “The primary goa

Slide 10: Contrave: A Differentiated US Launch
Resourcing Targeting Positioning Complete Approach For investor purposes only – not for use in product promotion Contrave ® : A Differentiated US Launch 900 sales representatives, market leading SOV Large experienced managed care organization Significant marketing budget 75,000 physicians 50% curren

Slide 11: Contrave Demonstrated Meaningful Efficacy in Phase 3
Weight loss over time in the completer population: COR-I Trial Combining Contrave with intensive BMOD drove more weight loss (COR-BMOD completer analysis) For investor purposes only – not for use in product promotion Contrave ® Demonstrated Meaningful Efficacy in Phase 3 ITT-LOCF -2 -4 -6 -8 -10 -12

Slide 12: Pricing Strategy Facilitates Adoption and Access
For investor purposes only – not for use in product promotion Pricing Strategy Facilitates Adoption and Access for both Covered and Cash Paying Patient Progressive Savings Designed to Help Reduce Patient Out of Pocket Costs $55 $70 $45 $60 Commercially covered Non-covered/ cash pay Months 1 & 2 Mont

Slide 13: Scale Down Provides Personalized Weight Management Support
For investor purposes only – not for use in product promotion Program entails 4 easy steps – Complete survey which enables personalized feedback – Weigh-in daily on a wireless-enabled scale – Receive text-based personalized feedback from Scale Down after weigh-in – Receive weekly lessons via email t

Slide 14: Early Launch Results are Encouraging
For investor purposes only – not for use in product promotion Early Launch Results are Encouraging Source: IMS Data Christmas / NY Thanksgiving Calling on writers and non writers with early success in both Reps are experiencing good access with long call times 900 reps provide dominant share of voic

Slide 15: The US Obesity Pharmacotherapy Market is Growing with Branded Products
Growth in total anti-obesity Rxs Growth in branded anti-obesity Rxs For investor purposes only – not for use in product promotion The US Obesity Pharmacotherapy Market is Growing with Introduction of Branded Products 6% 11% 537% 107% 2014E 2014E Source: IMS Data

Slide 16: Mysimba is First Weight Management Drug to Receive Positive CHMP Opinion in Nearly a Decade
For investor purposes only – not for use in product promotion Mysimba™ is First Weight Management Drug to Receive Positive CHMP Opinion in Nearly a Decade Positive CHMP opinion December 2014 EU authorization expected February 2015 Expected to be one of two oral weight management drugs on market in E

Slide 17: Significant ex-US Sales Potential for Contrave / Mysimba
For investor purposes only – not for use in product promotion Ex-US Historic Anti-Obesity Sales in 2007 ~ $1.4 billion Europe 43% ROW 57% Historic Anti-Obesity Sales in select countries Significant ex-US Sales Potential for Contrave ® / Mysimba™ Country Sales (2007) Middle East $54.2M Russia $48.8M

Slide 18: Life Cycle Development Opportunities for Contrave / Mysimba
For investor purposes only – not for use in product promotion Exciting Life Cycle Development Opportunities for Contrave ® / Mysimba™ Fixed dose combination with an approved diabetes drug, e.g., DPP4 and/or SGLT2 – Attractive opportunity under evaluation for patients with diabetes who are overweight

Slide 19: Broad and Growing Patent Estate Could Yield Protection Through 2034
Binge Eating (methods) Major Depression (methods) Visceral Fat (methods) Titration / Dose Pack (methods & devices) Tri-layer (methods & compositions) Food Cravings / Titration (methods) Insulin Sensitivity (methods & compositions) Weber / Cowley (methods & compositions) Nal SR (methods & composition

Slide 20: Solid Financial Position
For investor purposes only – not for use in product promotion Solid Financial Position Revenue drivers Tiered royalties of 20-35% on net sales in North America $15 million anniversary milestones to be paid in 2015, 2016, 2017 Potential sales milestones up to $880M Proceeds from potential ROW partner

Slide 21: 2015 Focus for Orexigen
For investor purposes only – not for use in product promotion 2015 Focus for Orexigen Successful US launch EU approval and ROW licensing Continue to strengthen patent portfolio Lifecycle development programs

Slide 22: Orexigen
is OREXIGEN
Source: SEC EDGAR · 8-K filed Jan 12, 2015
More decks from Orexigen Therapeutics Inc
Corporate Update (January 2018)17 slides · Jan 19, 2018
Corporate Update (January 2018)21 slides · Jan 8, 2018
BIO Investor Forum 201732 slides · Oct 16, 2017
Cantor Fitzgerald Healthcare Conference 201736 slides · Sep 26, 2017
Corporate Update (March 2017)56 slides · Mar 8, 2017
Investor Conferences February 13-17, 201755 slides · Feb 9, 2017